Key Takeaway: Cognition Therapeutics has completed enrollment for its Phase 2 SHIMMER study, which is investigating the efficacy of CT1812 in patients with mild-to-moderate dementia with Lewy bodies. This marks a significant step in the clinical development of CT1812, aimed at addressing this challenging condition. Further results from the study will be awaited to assess the drug's potential.
Price reaction · baseline $1.95 (2024-04-26 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close
-1%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.